Skip to main content

Advertisement

SpringerLink
Log in

Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK2) in postmenopausal RA patients

  • Original Article
  • Published:
Modern Rheumatology

Abstract

Objectives

We aimed to evaluate the clinical efficacy of monotherapy with alendronate and combined therapy with alendronate and menatetrenone (vitamin K2 [VitK2]) in postmenopausal rheumatoid arthritis (RA) patients with osteoporosis or osteopenia.

Methods

Sixty-two postmenopausal RA patients with untreated osteoporosis or osteopenia (lumbar spine bone density ≤80 % of young adult mean [YAM]) were enrolled: 39 had abnormal serum undercarboxylated osteocalcin (ucOC) levels (>4.5 ng/mL) and received combined therapy with alendronate (35 mg/week) and VitK2 (45 mg/day) (ALN + K group); 23 had normal ucOC levels (≤4.5 ng/mL) and received alendronate monotherapy (35 mg/week) (ALN group). The clinical results for the 57 patients in both groups were evaluated after 1-year treatment.

Results

The mean baseline/follow-up (FU) lumbar spine bone density (%YAM) values were 73.0/76.8 % (P < 0.01) in the ALN + K group and 77.0/80.3 % (P < 0.01) in the ALN group; a significant increase was shown in both groups. Mean proximal femoral bone density values at baseline/FU were 71.4/73.8 (P < 0.01) in the ALN + K group and 71.4/71.6 % (not significant; NS) in the ALN group; a significant increase was shown in the ALN + K group only. Serum ucOC levels were normalized in the ALN + K group at FU. At FU, bone metabolism markers [bone-specific alkaline phosphatase (BAP) and N-terminal cross-linked telopeptides of type I collagen] were decreased in both groups. One patient in the ALN + K group and three in the ALN group suffered new fractures.

Conclusions

Combined therapy with alendronate and VitK2 decreases bone metabolism marker levels and serum ucOC levels, and increases lumbar spine and femoral neck bone density in postmenopausal RA patients with abnormal ucOC levels and osteoporosis or osteopenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43:522–30.

    Article  PubMed  CAS  Google Scholar 

  2. Van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104–12.

    Article  PubMed  Google Scholar 

  3. No authors listed. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000;17:1–45.

  4. Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32:120–6.

    Article  PubMed  CAS  Google Scholar 

  5. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten year’s experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–99.

    Article  PubMed  CAS  Google Scholar 

  6. Feskanich D, Weber P, Willet WC, Rockett H, Booth SL, Colditz GA. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr. 1999;69:74–9.

    PubMed  CAS  Google Scholar 

  7. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137–48.

    Article  PubMed  CAS  Google Scholar 

  8. Yilmaz L, Ozoran K, Gündüz OH, Uçan H, Yücel M. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int. 2001;20:65–9.

    Article  PubMed  CAS  Google Scholar 

  9. Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, et al. Prevention of loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int. 2000;11:331–7.

    Article  PubMed  CAS  Google Scholar 

  10. Kai M, Makino S, Yuasa M, Nishijima T. Study of bone vitamin K deficiency of RA patients-Evaluation with the measurement of ucOC in serum. Rheumatology.2009;42:133–8 (in Japanese).

  11. Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H. Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab. 2008;26:260–4.

    Article  PubMed  CAS  Google Scholar 

  12. Nakayama H, Hagiwara F, Tohma S. Three-year effects of bisphosphonates on treatment of osteoporosis and on reducing the risk for vertebral fractures of rheumatoid arthritis patients. Osteoporos Japan. 2007;15:13–8.

    Google Scholar 

  13. Iwamoto J, Takeda T, Ichimura S. Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis. J Orthop Sci. 2000;5:546–51.

    Article  PubMed  CAS  Google Scholar 

  14. Knapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int. 2007;18:963–72.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Hoshigaoka Koseinenkin Hospital, 4-8-1 Hoshigaoka, Hirakata, Osaka, 573-8511, Japan

    Kouji Suzuki, Shigeyoshi Tsuji, Takanobu Nakase & Masayuki Hamada

  2. Osaka Trauma and Microsurgery Center, Seikeikai Hospital, Sakai, Osaka, Japan

    Yaeko Fukushima

  3. Department of Orthopaedics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

    Tetsuya Tomita & Hideki Yoshikawa

Authors
  1. Kouji Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigeyoshi Tsuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yaeko Fukushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takanobu Nakase
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masayuki Hamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tetsuya Tomita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hideki Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigeyoshi Tsuji.

About this article

Cite this article

Suzuki, K., Tsuji, S., Fukushima, Y. et al. Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK2) in postmenopausal RA patients. Mod Rheumatol 23, 450–455 (2013). https://doi.org/10.1007/s10165-012-0678-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-012-0678-x

Keywords

Search

Navigation